Basic Quinolinonyl Diketo Acid Derivatives as Inhibitors of HIV Integrase and their Activity against RNase H Function of Reverse Transcriptase

A series of antiviral basic quinolinonyl diketo acid derivatives were developed as inhibitors of HIV-1 IN. Compounds 12d,f,i inhibited HIV-1 IN with IC50 values below 100 nM for strand transfer and showed a 2 order of magnitude selectivity over 3′-processing. These strand transfer selective inhibitors also inhibited HIV-1 RNase H with low micromolar potencies. Molecular modeling studies based on both the HIV-1 IN and RNase H catalytic core domains provided new structural insights for the future development of these compounds as dual HIV-1 IN and RNase H inhibitors.

[1]  Olan Dolezal,et al.  Parallel Screening of Low Molecular Weight Fragment Libraries , 2013, Journal of biomolecular screening.

[2]  Y. Pommier,et al.  Activities, crystal structures, and molecular dynamics of dihydro-1H-isoindole derivatives, inhibitors of HIV-1 integrase. , 2013, ACS chemical biology.

[3]  Wei Yang,et al.  Complexes of HIV-1 RT, NNRTI and RNA/DNA hybrid reveal a structure compatible with RNA degradation , 2013, Nature Structural &Molecular Biology.

[4]  Thomas S. Peat,et al.  Small Molecule Inhibitors of the LEDGF Site of Human Immunodeficiency Virus Integrase Identified by Fragment Screening and Structure Based Design , 2012, PloS one.

[5]  J. Newman,et al.  Crystal Structures of Novel Allosteric Peptide Inhibitors of HIV Integrase Identify New Interactions at the LEDGF Binding Site , 2011, Chembiochem : a European journal of chemical biology.

[6]  Yves Pommier,et al.  Structural and Functional Analyses of the Second-Generation Integrase Strand Transfer Inhibitor Dolutegravir (S/GSK1349572) , 2011, Molecular Pharmacology.

[7]  S. Piscitelli,et al.  Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of dolutegravir as 10-day monotherapy in HIV-1-infected adults , 2011, AIDS.

[8]  R. D. Santo.  Diketo Acids Derivatives as Dual Inhibitors of Human Immunodeficiency Virus Type 1 Integrase and the Reverse Transcriptase RNase H Domain , 2011 .

[9]  E. Arnold,et al.  Synthesis, activity, and structural analysis of novel α-hydroxytropolone inhibitors of human immunodeficiency virus reverse transcriptase-associated ribonuclease H. , 2011, Journal of medicinal chemistry.

[10]  Xiaohong Liu,et al.  Structural and Binding Analysis of Pyrimidinol Carboxylic Acid and N-Hydroxy Quinazolinedione HIV-1 RNase H Inhibitors , 2011, Antimicrobial Agents and Chemotherapy.

[11]  J. Newman,et al.  Structural Basis for a New Mechanism of Inhibition of H I V-1 Integrase Identified by Fragment Screening and Structure-Based Design , 2011, Antiviral chemistry & chemotherapy.

[12]  F. Bailly,et al.  Magnesium chelating 2-hydroxyisoquinoline-1,3(2H,4H)-diones, as inhibitors of HIV-1 integrase and/or the HIV-1 reverse transcriptase ribonuclease H domain: discovery of a novel selective inhibitor of the ribonuclease H function. , 2011, Journal of medicinal chemistry.

[13]  M. Parker,et al.  Fragment‐Based Design of Ligands Targeting a Novel Site on the Integrase Enzyme of Human Immunodeficiency Virus 1 , 2011, ChemMedChem.

[14]  Maxwell D. Cummings,et al.  Molecular mechanisms of retroviral integrase inhibition and the evolution of viral resistance , 2010, Proceedings of the National Academy of Sciences.

[15]  Goedele N. Maertens,et al.  The mechanism of retroviral integration through X-ray structures of its key intermediates , 2010, Nature.

[16]  X. Zhuang,et al.  Structure-Activity Analysis of Vinylogous Urea Inhibitors of Human Immunodeficiency Virus-Encoded Ribonuclease H , 2010, Antimicrobial Agents and Chemotherapy.

[17]  Y. Pommier,et al.  Scaffold rearrangement of dihydroxypyrimidine inhibitors of HIV integrase: Docking model revisited. , 2010, Bioorganic & medicinal chemistry letters.

[18]  A. Marchand,et al.  Rational design of small-molecule inhibitors of the LEDGF/p75-integrase interaction and HIV replication. , 2010, Nature chemical biology.

[19]  Christopher L. Daniels,et al.  Structural Basis for the Inhibition of RNase H Activity of HIV-1 Reverse Transcriptase by RNase H Active Site-Directed Inhibitors , 2010, Journal of Virology.

[20]  M. Parker,et al.  Crystal structure of the HIV‐1 integrase core domain in complex with sucrose reveals details of an allosteric inhibitory binding site , 2010, FEBS letters.

[21]  A. Engelman,et al.  Retroviral intasome assembly and inhibition of DNA strand transfer , 2010, Nature.

[22]  A. D. Clark,et al.  Structure of HIV-1 reverse transcriptase with the inhibitor beta-Thujaplicinol bound at the RNase H active site. , 2009, Structure.

[23]  C. Van Lint,et al.  Structural and theoretical studies of [6-bromo-1-(4-fluorophenylmethyl)-4(1H)-quinolinon-3-yl)]-4-hydroxy-2-oxo-3-butenoïc acid as HIV-1 integrase inhibitor. , 2009, Bioorganic & medicinal chemistry letters.

[24]  Yves Pommier,et al.  Comparison of raltegravir and elvitegravir on HIV-1 integrase catalytic reactions and on a series of drug-resistant integrase mutants. , 2008, Biochemistry.

[25]  Y. Pommier,et al.  Novel Quinolinonyl Diketo Acid Derivatives as HIV-1 Integrase Inhibitors: Design, Synthesis, and Biological Activities , 2008, Journal of medicinal chemistry.

[26]  Zhengqiang Wang,et al.  Design and synthesis of dual inhibitors of HIV reverse transcriptase and integrase: introducing a diketoacid functionality into delavirdine. , 2008, Bioorganic & medicinal chemistry.

[27]  Zhengqiang Wang,et al.  Synthesis of pyrimidine and quinolone conjugates as a scaffold for dual inhibitors of HIV reverse transcriptase and integrase. , 2008, Bioorganic & medicinal chemistry letters.

[28]  Nouri Neamati,et al.  HIV‐1 integrase inhibitors: 2005–2006 update , 2008, Medicinal research reviews.

[29]  Y. Pommier,et al.  Madurahydroxylactone Derivatives as Dual Inhibitors of Human Immunodeficiency Virus Type 1 Integrase and RNase H , 2007, Antimicrobial Agents and Chemotherapy.

[30]  P. Bellecave,et al.  Cellular uptake of ODNs in HIV-1 human-infected cells: a role for viral particles in DNA delivery? , 2007, Oligonucleotides.

[31]  C. Salomon,et al.  Rationally designed dual inhibitors of HIV reverse transcriptase and integrase. , 2007, Journal of medicinal chemistry.

[32]  B. Conway,et al.  The Role of Adherence to Antiretroviral Therapy in the Management of HIV Infection , 2007, Journal of acquired immune deficiency syndromes.

[33]  C. Katlama,et al.  Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial , 2007, The Lancet.

[34]  C. Kovacs,et al.  Antiretroviral Activity, Pharmacokinetics, and Tolerability of MK-0518, a Novel Inhibitor of HIV-1 Integrase, Dosed As Monotherapy for 10 Days in Treatment-Naive HIV-1-Infected Individuals , 2006, Journal of acquired immune deficiency syndromes.

[35]  B. Clotet,et al.  Benefits and concerns of simplification strategies in HIV-infected patients. , 2006, The Journal of antimicrobial chemotherapy.

[36]  Mahindra T. Makhija.  Designing HIV integrase inhibitors--shooting the last arrow. , 2006, Current medicinal chemistry.

[37]  M. Kozal,et al.  The hunt for HIV-1 integrase inhibitors. , 2006, AIDS patient care and STDs.

[38]  R. Dayam,et al.  HIV‐1 integrase inhibitors: 2003–2004 update , 2006 .

[39]  Y. Pommier,et al.  Preferential Inhibition of the Magnesium-Dependent Strand Transfer Reaction of HIV-1 Integrase by α-Hydroxytropolones , 2006, Molecular Pharmacology.

[40]  Y. Pommier,et al.  Novel bifunctional quinolonyl diketo acid derivatives as HIV-1 integrase inhibitors: design, synthesis, biological activities, and mechanism of action. , 2006, Journal of medicinal chemistry.

[41]  C. Isel,et al.  Inhibition of Human Immunodeficiency Virus Type 1 Reverse Transcriptase, RNase H, and Integrase Activities by Hydroxytropolones , 2005, Antimicrobial Agents and Chemotherapy.

[42]  A. Engelman,et al.  Structural basis for the recognition between HIV-1 integrase and transcriptional coactivator p75. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[43]  Wei Yang,et al.  Crystal Structures of RNase H Bound to an RNA/DNA Hybrid: Substrate Specificity and Metal-Dependent Catalysis , 2005, Cell.

[44]  Y. Pommier,et al.  Integrase inhibitors to treat HIV/Aids , 2005, Nature Reviews Drug Discovery.

[45]  S. L. Le Grice,et al.  Selective inhibition of HIV-1 reverse transcriptase-associated ribonuclease H activity by hydroxylated tropolones , 2005, Nucleic acids research.

[46]  R. Di Santo,et al.  6-[1-(4-Fluorophenyl)methyl-1H-pyrrol-2-yl)]-2,4-dioxo-5-hexenoic acid ethyl ester a novel diketo acid derivative which selectively inhibits the HIV-1 viral replication in cell culture and the ribonuclease H activity in vitro. , 2005, Antiviral research.

[47]  Conrad C. Huang,et al.  UCSF Chimera—A visualization system for exploratory research and analysis , 2004, J. Comput. Chem..

[48]  F. Bailly,et al.  Spectroscopic studies of diketoacids-metal interactions. A probing tool for the pharmacophoric intermetallic distance in the HIV-1 integrase active site. , 2004, Journal of medicinal chemistry.

[49]  Y. Pommier,et al.  HIV-1 integrase inhibitors: a decade of research and two drugs in clinical trial. , 2004, Current topics in medicinal chemistry.

[50]  F. Bailly,et al.  Structure-activity relationships of HIV-1 integrase inhibitors--enzyme-ligand interactions. , 2003, Current medicinal chemistry.

[51]  M. Chesney,et al.  Adherence to HAART regimens. , 2003, AIDS patient care and STDs.

[52]  D. Hazuda,et al.  Inhibition of HIV-1 Ribonuclease H by a Novel Diketo Acid, 4-[5-(Benzoylamino)thien-2-yl]-2,4-dioxobutanoic Acid* , 2003, The Journal of Biological Chemistry.

[53]  R. Altmeyer,et al.  DNA aptamers derived from HIV-1 RNase H inhibitors are strong anti-integrase agents. , 2002, Journal of molecular biology.

[54]  J. Gallant,et al.  Simplification of antiretroviral treatment--how to sustain success, reduce toxicity and ensure adherence avoiding PI use. , 2002, AIDS reviews.

[55]  Wei Yang,et al.  Structure of a two‐domain fragment of HIV‐1 integrase: implications for domain organization in the intact protein , 2001, The EMBO journal.

[56]  F. Bushman,et al.  Identification of a small-molecule binding site at the dimer interface of the HIV integrase catalytic domain. , 2001, Acta crystallographica. Section D, Biological crystallography.

[57]  R M Stroud,et al.  Crystal structure of the HIV-1 integrase catalytic core and C-terminal domains: a model for viral DNA binding. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[58]  G. Cohen,et al.  Structure of the HIV-1 integrase catalytic domain complexed with an inhibitor: a platform for antiviral drug design. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[59]  T. Chun,et al.  Latent reservoirs of HIV: obstacles to the eradication of virus. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[60]  F. Bushman,et al.  The mobility of an HIV-1 integrase active site loop is correlated with catalytic activity. , 1999, Biochemistry.

[61]  G L Verdine,et al.  Structure of a covalently trapped catalytic complex of HIV-1 reverse transcriptase: implications for drug resistance. , 1998, Science.

[62]  V. Mikol,et al.  Crystal structures of the catalytic domain of HIV-1 integrase free and complexed with its metal cofactor: high level of similarity of the active site with other viral integrases. , 1998, Journal of molecular biology.

[63]  D. Davies,et al.  Three new structures of the core domain of HIV-1 integrase: an active site that binds magnesium. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[64]  W. L. Jorgensen,et al.  Development and Testing of the OPLS All-Atom Force Field on Conformational Energetics and Properties of Organic Liquids , 1996 .

[65]  S. Sarafianos,et al.  Biochemical analysis of catalytically crucial aspartate mutants of human immunodeficiency virus type 1 reverse transcriptase. , 1996, Biochemistry.

[66]  A. D. Clark,et al.  Insights into DNA polymerization mechanisms from structure and function analysis of HIV-1 reverse transcriptase. , 1995, Biochemistry.

[67]  A. Engelman,et al.  Crystal structure of the catalytic domain of HIV-1 integrase: similarity to other polynucleotidyl transferases. , 1994, Science.

[68]  A. D. Clark,et al.  Crystal structure of human immunodeficiency virus type 1 reverse transcriptase complexed with double-stranded DNA at 3.0 A resolution shows bent DNA. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[69]  Y. Pommier,et al.  Structural and Functional Analyses of the Second-Generation Integrase Strand Transfer Inhibitor Dolutegravir (S/GSK1349572) , 2011, Molecular Pharmacology.

[70]  R. Di Santo.  Diketo acids derivatives as dual inhibitors of human immunodeficiency virus type 1 integrase and the reverse transcriptase RNase H domain. , 2011, Current medicinal chemistry.

[71]  Yves Pommier,et al.  Structural and Functional Analyses of the Second-Generation Integrase Strand Transfer Inhibitor Dolutegravir , 2011 .

[72]  P. Yeni.  Update on HAART in HIV. , 2006, Journal of hepatology.

[73]  Philippe Cotelle,et al.  Patented HIV-1 integrase inhibitors (1998-2005). , 2006, Recent patents on anti-infective drug discovery.

[74]  A. Engelman,et al.  Structural basis for the recognition between HIV-1 integrase and transcriptional coactivator p 75 , 2005 .